

Clinical trials of Taxanes for advanced breast cancer (metastatic) in all type of patients

TrialResults-center www.trialresultscenter.org

1 A CLASSER

Trial	Treatments	Patients	Trials design and methods
vs			
AGO , 1998 n=NA follow-up:	-	-	
EU-1 , 2004 n=NA follow-up:	-	-	
Lyman n=NA follow-up:	-	-	
Nabholtz n=NA follow-up:	-	-	
TRAVIOTA n=NA follow-up:	-	-	
Yardley , 2009 n=NA follow-up:	weekly docetaxel versus liposomal doxorubicin	-	

References

AGO, 1998:

Konecny G, Kuhn W, Sattler D, Thomssen C, Bauknecht T, Taxane-containing regimens for metastatic breast cancer (Review) 27

Schroeder W, Luck HJ, Thomssen C, Mobus V, Kuhn W, von Minckwitz G. Phase III multicenter trial of epirubicin-paclitaxel vs epirubicin-cyclophosphamide firstline therapy of metastatic breast cancer. An AGO Study protocol. European Society for Medical Oncology Congress Proceedings; 1998. 1998; Vol. 9 (Supplement 4):Abstract 560.

von Minckwitz G, Kuhn W, Thomssen C, Untch M, Bauknecht T, Eidtmann D, et al. Phase III trial comparing epirubicin/paclitaxel vs epirubicin/cyclophosphamide as first line treatment in metastatic breast cancer: preliminary results of a German AGO trial. European Journal of Cancer 1998;34 (Supplement 5):S90.

EU-1, 2004:

Heidemann E, Minckwitz GV, Hollander N, Souchon R, Clemens M, Mahike M, et al. Mitoxantrone plus docetaxel vs single agent mitoxantrone in metastatic breast cancer (MBC): results of a multicenter randomized trial. Proceedings of American Society of Clinical Oncology; 2004. 2004; Vol. 22, No 14S:637. NCT00002544. Mitoxantrone with or without docetaxel in treati

Lyman, 0:

Nabholtz, 0:

TRAVIOTA, 0:

Yardley, 2009:

Yardley, DA A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer. Clin. Breast Cancer 2009;9:247-52 [[19933081](#)] [10.3816/CBC.2009.n.042](#)

2 nab-paclitaxel

Trial	Treatments	Patients	Trials design and methods
nab-paclitaxel vs docetaxel			
Gradishar , 2009 [NCT00274456] n=302 follow-up:	weekly and every 3 week (q3w) nab-paclitaxel versus docetaxel	first-line treatment in patients with MBC	
nab-paclitaxel + gemcitabine or carboplatin vs gemcitabine or carboplatin			
tnAcity ongoing [NCT01881230] n=NA follow-up:	Weekly Nab-Paclitaxel in Combination With Gemcitabine or Carboplatin versus Gemcitabine or Carboplatin	-	
nab-paclitaxel +gencotabine vs gemcitabine			
Roy , 2008 [NCT00110084] n=50 follow-up:	-	patients with previously untreated metastatic breast cancer	

References

Gradishar, 2009:

Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-9 [[19470941](#)]

Dranitsaris G, Coleman R, Gradishar W nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat 2010;119:717-24 [[19495958](#)]

Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P, McGuire JR, Iglesias J Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer 2012;12:313-21 [[22728026](#)]

Aapro M, Tjulandin S, Bhar P, Gradishar W Weekly nab-paclitaxel is safe and effective in ?65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast 2011;20:468-74 [[21843943](#)]

Aapro M, Tjulandin S, Bhar P, Gradishar W Weekly nab-paclitaxel is safe and effective in ?65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast 2011;20:468-74 [[21843943](#)]

tnAcity, :

Roy, 2008:

Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20:449-53 [[19087987](#)]

Moreno-Aspitia A, Perez EA North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin Breast Cancer 2005;6:361-4 [16277889]

Roy V, LaPlant BR, Gross GG, et al. NCCTG phase II trial N0531 of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC). [Abstract] J Clin Oncol 25 (Suppl 18): A-1048, 2007.

3 taxanes alone

Trial	Treatments	Patients	Trials design and methods
paclitaxel vs capecitabine			
Talbot , 2002 n=NA follow-up:	i.v. paclitaxel (175 mg m(-2), versus 3-week cycles of intermittent oral capecitabine (1255 mg m(-2) twice daily, days 1-14,	-	
paclitaxel vs cisplatin, etoposide			
TOG , 2005 n=NA follow-up:	-	-	
paclitaxel vs CMFP			
ANZ TITG , 1999 n=NA follow-up:	paclitaxel 200 mg/m(2) intravenously (IV) over 3 hours for eight cycles (24 weeks) versus standard cyclophosphamide 100 mg/m(2)/d orally on days 1 to 14, methotrexate 40 mg/m(2) IV on days 1 and 8, fluorouracil 600 mg/m(2) IV on days 1 and 8, and prednisone 40 mg/m(2)/d orally on days 1 to 14 (CMFP) for six cycles (24 weeks) with epirubicin re	front-line therapy in untreated metastatic breast cancer	
docetaxel vs doxorubicin			
303 Study Group , 1999 n=161/165 follow-up:	intravenous infusion of docetaxel 100 mg/m(2) every 3 weeks for a maximum of seven treatment cycles. versus intravenous infusion of doxorubicin 75 mg/m(2) every 3 weeks for a maximum of seven treatment cycles.	patients with metastatic breast cancer who had received previous alkylating agent-containing chemotherapy	
paclitaxel vs doxorubicin			
ECOG E1193 (B) , 2003 n=NA follow-up:	paclitaxel (175 mg/m(2)/24 h), versus doxorubicin (60 mg/m(2)),	patients with metastatic breast cancer	
EORTC 10923 , 2000 n=NA follow-up:	-	first-line therapy of advanced breast cancer	
docetaxel vs doxorubicin + cyclophosphamide			

continued...

Trial	Treatments	Patients	Trials design and methods
JCOG , 2005 n=NA follow-up:	-	first-line chemotherapy in metastatic breast cancer	
docetaxel vs fluorouracil, vinorelbine			
TXT Group , 2002 n=NA follow-up:	docetaxel (100 mg m(-2)) every 3 weeks versus 5-fluorouracil+vinorelbine: 5-fluorouracil (750 mg m(-2) per day continuous infusion) D1-5 plus vinorelbine (25 mg m(-2)) D1 and D5 of each 3-week cycle	patients with metastatic breast cancer after failure of neo/adjuvant or one line of palliative anthracycline-based chemotherapy	
paclitaxel vs mitomycin			
Dieras , 1995 n=NA follow-up:	paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks versus mitomycin 12 mg/m2 given as an intravenous infusion every 6 weeks	advanced breast cancer	
docetaxel vs mitomycin, vinblastine			
304 Study Group , 1999 n=203/189 follow-up:	docetaxel 100 mg/m2 intravenously (i.v.) every 3 weeks versus mitomycin 12 mg/m2 i.v. every 6 weeks plus vinblastine 6 mg/m2 i.v. every 3 weeks	patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy	open-label
docetaxel vs sequential methotrexate and 5-fluorouracil			
Sjostrom , 1999 n=143/139 follow-up:	Docetaxel at a dose of 100 mg/m2 every 3 weeks versus sequential methotrexate and 5-fluorouracil	patients with advanced breast cancer who had failed previous anthracycline treatment	
docetaxel vs vinorelbine			
Meier , 2008 n=NA follow-up:	weekly docetaxel (DOC), 6 weekly doses per 8-week cycle versus Weekly vinorelbine	after failing anthracycline treatment	

References

Talbot, 2002:

Talbot, DC Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br. J. Cancer 2002;86:1367-72 [[11986765](#)] [10.1038/sj.bjc.6600261](#)

TOG, 2005:

Icli, F Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. Br. J. Cancer 2005;92:639-44 [[15726120](#)] [10.1038/sj.bjc.6602388](#)

ANZ TITG, 1999:

Bishop, JF A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. Semin. Oncol. 1997;24:S17-5-S17-9 [[9374084](#)] [NA](#)

Bishop, JF Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. *J. Clin. Oncol.* 1999;17:2355-64 [[10561297](#)] [NA](#)

Bishop, JF Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand. *Oncology (Williston Park, N.Y.)* 1997;11:19-23 [[9144686](#)] [NA](#)

303 Study Group, 1999:

Chan, S Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. *J. Clin. Oncol.* 1999;17:2341-54 [[10561296](#)] [NA](#)

Nabholtz, JM Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results. *Semin. Oncol.* 1998;25:4-9 [[9865685](#)] [NA](#)

Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al. A phase III study of taxotere vs doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regimen. *Breast Cancer Research and Treatment; San Antonio Breast Cancer Symposium; 1997; San Antonio. 1997; Vol. 46:Abstract 1.* [MEDLINE: 4776]

Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al. A phase III study of taxotere vs doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regimen. *Breast Cancer Research and Treatment; San Antonio Breast Cancer Symposium; 1997; San Antonio. 1997; Vol. 46:Abstract 1.* [MEDLINE: 4776]

ECOG E1193 (B), 2003:

Sledge, GW Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). *J. Clin. Oncol.* 2003;21:588-92 [[12586793](#)] [NA](#)

EORTC 10923, 2000:

Kramer, JA Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. *Eur. J. Cancer* 2000;36:1498-506 [[10930797](#)] [NA](#)

Kramer, JA Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. *Eur. J. Cancer* 2000;36:1488-97 [[10930796](#)] [NA](#)

Paridaens, R Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. *J. Clin. Oncol.* 2000;18:724-33 [[10673513](#)] [NA](#)

Piccart-Gebhart, MJ An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer. *Semin. Oncol.* 1996;23:11-5 [[8893893](#)] [NA](#)

Bruning P, Piccart MJ, Klijn J, Gamucci T, Kusenda Z, Roy JA, et al. Paclitaxel (P) versus doxorubicin (D) as first line chemotherapy (CT) in advanced breast cancer (ABC): a randomized trial with crossover of the EORTC-IDBBC in collaboration with EORTC-ECSG. *European Journal of Cancer (Supplement)* 1996;32(2):50.

Paridaens R, Bruning P, Calabresi F, Awada A, Roy JA, Kusenda Z, et al. Taxol or doxorubicin as first line chemotherapy in advanced breast cancer (ABC). A prospective randomized phase II study with crossover. *European Journal of Cancer (Supplement)* 1995;31A(5):S75.

Bruning P, Piccart MJ, Klijn J, Gamucci T, Kusenda Z, Roy JA, et al. Paclitaxel (P) versus doxorubicin (D) as first line chemotherapy (CT) in advanced breast cancer (ABC): a randomized trial with crossover of the EORTC-IDBBC in collaboration with EORTC-ECSG. *European Journal of Cancer (Supplement)* 1996;32(2):50.

Paridaens R, Bruning P, Calabresi F, Awada A, Roy JA, Kusenda Z, et al. Taxol or doxorubicin as first line chemotherapy in advanced breast cancer (ABC). A prospective randomized phase II study with crossover. *European Journal of Cancer (Supplement)* 1995;31A(5):S75.

JCOG, 2005:

Katsumata, N Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). *Ann. Oncol.* 2009;20:1210-5 [[19254942](#)] [10.1093/annonc/mdn781](#)

Katsumata N, Minami H, Aogi K, Tabei T, Sano M, Masuda N, et al. Phase III trial of doxorubicin (A)/ cyclophosphamide (C) (AC), docetaxel (D), and alternating AC and D (AC-D) as front-line chemotherapy for metastatic breast cancer (MBC): Japan Clinical Oncology Group trial (JCOG9802). *Journal of Clinical Oncology; Proceedings of American Society of Clinical Oncology; 2005. 2005; Vol. 23, No 16S:Abstract 521.*

TXT Group, 2002:

Bonnetterre, J Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. *Br. J. Cancer* 2002;87:1210-5 [[12439707](#)] [10.1038/sj.bjc.6600645](#)

Dieras, 1995:

Dieras, V Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. *Semin. Oncol.* 1995;22:33-9 [7638640] NA

304 Study Group, 1999:

Nabholtz, JM Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results. *Semin. Oncol.* 1998;25:4-9 [9865685] NA

Nabholtz, JM Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. *J. Clin. Oncol.* 1999;17:1413-24 [10334526] NA

Nabholtz, JM Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. *Oncology (Williston Park, N.Y.)* 1997;11:25-30 [9364538] NA

Sjostrom, 1999:

Hakamies-Blomqvist, L Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group. *Eur. J. Cancer* 2000;36:1411-7 [10899655] NA

Luoma, ML Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. *Eur. J. Cancer* 2003;39:1370-6 [12826039] NA

Sjstrm, J Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. *Eur. J. Cancer* 1999;35:1194-201 [10615229] NA

Meier, 2008:

Meier, CR Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment. *Onkologie* 2008;31:447-53 [18787352] 10.1159/000140453

4 taxanes in combination

9

Trial	Treatments	Patients	Trials design and methods
docetaxel + doxorubicin vs doxorubicin + cyclophosphamide			
306 Study Group , 2003 n=214/215 follow-up:	doxorubicin 50 mg/m(2) plus docetaxel 75 mg/m(2) versus doxorubicin 60 mg/m(2) plus cyclophosphamide 600 mg/m(2)	first-line chemotherapy for metastatic breast cancer	
paclitaxel + doxorubicin vs doxorubicin + cyclophosphamide			
EORTC 10961 , 2002 n=NA follow-up:	Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide	first-line chemotherapy in metastatic breast cancer	
docetaxel + epirubicin vs epirubicin, cyclophosphamide			
Blohmer , 2010 n=NA follow-up:	ED (epirubicin 75 mg/m(2) and docetaxel 75 mg/m(2)) versus EC (epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2)).	first-line therapy for women with metastatic breast cancer	
paclitaxel + epirubicin vs epirubicin, cyclophosphamide			

continued...

Trial	Treatments	Patients	Trials design and methods
UKCCCR AB01 , 1997 n=NA follow-up:	EP (epirubicin 75 mg/m ² and paclitaxel 200 mg/m ²) versus EC (epirubicin 75 mg/m ² and cyclophosphamide 600 mg/m ²) administered intravenously every 3 weeks for a maximum of six cycles	first-line chemotherapy for metastatic breast cancer	
docetaxel + doxorubicin vs fluorouracil, doxorubicin, cyclophosphamide			
Bontenbal , 2005 n=NA follow-up:	AT (doxorubicin 50 mg/m ²) and docetaxel 75 mg/m ²) versus FAC (fluorouracil 500 mg/m ² , doxorubicin 50 mg/m ² , and cyclophosphamide 500 mg/m ²);	first-line chemotherapy in patients with metastatic breast cancer:	
paclitaxel + doxorubicin vs fluorouracil, doxorubicin, cyclophosphamide			
Jassem , 2001 n=NA follow-up:	-	first-line therapy for women with metastatic breast cancer	
docetaxel + epirubicin vs fluorouracil, epirubicin, cyclophosphamide			
Bonneterre , 2004 n=NA follow-up:	docetaxel 75 mg m(-2) plus epirubicin 75 mg m(-2) versus 5-fluorouracil 500 mg m(-2) plus epirubicin 75 mg m(-2) and cyclophosphamide 500 mg m(-2) intravenously once every 3 weeks for up to eight cycles	-	
gemcitabine, epirubicin, paclitaxel vs fluorouracil, epirubicin, cyclophosphamide			
CECOG BM1 , 2005 n=NA follow-up:	gemcitabine (1,000 mg/m ²), days 1 and 4), epirubicin (90 mg/m ²), day 1), and paclitaxel (175 mg/m ²), day 1) versus FU (500 mg/m ²), day 1), epirubicin (90 mg/m ²), day 1), and cyclophosphamide (500 mg/m ²), day 1)	first-line chemotherapy in metastatic breast cancer	
docetaxel + trastuzumab vs vinorelbine, trastuzumab			
HERNATA , 2011 n=NA follow-up:	docetaxel 100 mg/m ² day 1 versus vinorelbine 30 to 35 mg/m ² on days 1 and 8	first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer	

References

306 Study Group, 2003:

Nabholtz, JM Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J. Clin. Oncol. 2003;21:968-75 [12637459] NA

Luo, Z [Efficacy and Safety of Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease—a Multi-center Randomized Clinical Trial]. Sichuan Da Xue Xue Bao Yi Xue Ban 2015;46:485-7 [26121878] NA

EORTC 10961, 2002:

Biganzoli, L Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. *J. Clin. Oncol.* 2002;20:3114-21 [[12118025](#)] [NA](#)

Vaidya, AM Does a High-Risk Recommendation in Mammography Reports Increase Attendance at Breast Cancer Risk Assessment Clinic? *J Am Coll Radiol* 2015;NA: [[26187038](#)] [10.1016/j.jacr.2015.04.024](#)

Bottomley, A Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. *J. Clin. Oncol.* 2004;22:2576-86 [[15226325](#)] [10.1200/JCO.2004.02.037](#)

Blohmer, 2010:

Blohmer, JU Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial. *Ann. Oncol.* 2010;21:1430-5 [[20089562](#)] [10.1093/annonc/mdp585](#)

UKCCCR AB01, 1997:

Carmichael, J A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee. *Semin. Oncol.* 1997;24:S17-44-S17-47 [[9374092](#)] [NA](#)

Langley, RE Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. *J. Clin. Oncol.* 2005;23:8322-30 [[16293863](#)] [10.1200/JCO.2005.01.1817](#)

Bontenbal, 2005:

Bontenbal, M Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. *J. Clin. Oncol.* 2005;23:7081-8 [[16192591](#)] [10.1200/JCO.2005.06.236](#)

Bontenbal M, Braun JJ, Creemers GJ, de Boer AC, Janssen JTP, Leys MBL, et al. Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). *European Journal of Cancer Supplements* 2003;1(5):S2012.

Bontenbal M, Braun JJ, Creemers GJ, de Boer AC, Janssen JTP, Leys MBL, et al. Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). *European Journal of Cancer Supplements* 2003;1(5):S2012.

Jassem, 2001:

Jassem, J Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial. *Onkologie* 2009;32:468-72 [[19745590](#)] [10.1159/000226210](#)

Jassem, J Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. *J. Clin. Oncol.* 2001;19:1707-15 [[11251000](#)] [NA](#)

Pluzanska A, Jassem J, Jelic S, Gorbunova V, Mrcic-Krmpotic Z, Berzins J, et al. Randomized open-label phase III multicenter trial comparing TAXOL/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer. *European Journal of Cancer* 1999;35 (Supplement 4):S314.

Pluzanska A, Jassem J, Jelic S, Gorbunova V, Mrcic-Krmpotic Z, Berzins J, et al. Randomized open-label phase III multicenter trial comparing TAXOL/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer. *European Journal of Cancer* 1999;35 (Supplement 4):S314.

Bonnetterre, 2004:

Bonnetterre, J Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. *Br. J. Cancer* 2004;91:1466-71 [[15381937](#)] [10.1038/sj.bjc.6602179](#)

CECOG BM1, 2005:

Zielinski, C Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. *J. Clin. Oncol.* 2005;23:1401-8 [[15735116](#)] [10.1200/JCO.2005.12.106](#)

HERNATA, 2011:

Andersson, M Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. *J. Clin. Oncol.* 2011;29:264-71 [[21149659](#)] [10.1200/JCO.2010.30.8213](#)

5 weekly taxanes

Trial	Treatments	Patients	Trials design and methods
Weekly Docetaxel vs Every three weeks Docetaxel			
65279;Rivera , 2008 n=NA follow-up:	Weekly Docetaxel 3540 mg/m2 versus Every three weeks Docetaxel 75100 mg/m2	65279;Metastatic patients with metastatic breast cancer	open
Tabernero , 2004 n=NA follow-up:	Weekly Docetaxel 40 mg/m2 versus Every three weeks Docetaxel 100 mg/m2	Metastatic	
Sedky , 2002 n=NA	Weekly Docetaxel 35 mg/m2 versus Every three weeks Docetaxel 100 mg/m2	Metastatic	
Willemse , 2007 n=NA	Weekly Docetaxel 36 mg/m2 versus Every three weeks Docetaxel 100 mg/m2	Metastatic	
Weekly Paclitaxel vs Every three weeks Docetaxel			
Gradishar , 2009 n=NA follow-up:	Weekly Nab-paclitaxel 100 mg/m2 versus Every three weeks Docetaxel 100 mg/m2	Metastatic	
Fountzilias , 2008 n=NA follow-up:	Weekly Paclitaxel 80 mg/m2 versus Every three weeks Gemc. Docetaxel 75 mg/m2	Metastatic	
split dose vs Every three weeks Paclitaxel			
Khoo , 2006 n=NA follow-up:	split-dose paclitaxel or docetaxel in combination with gemcitabine versus Every three weeks Gemc. Paclitaxel 175 mg/m2	Metastatic patients with metastatic breast cancer (MBC) who had previously received anthracyclines	
Weekly Paclitaxel vs Every three weeks Paclitaxel			
CLGB 9840 (Seidman) , 2008 n=NA follow-up:	Weekly Paclitaxel 80 mg/m2 versus Every three weeks Paclitaxel 175 mg/m2	Metastatic	
Fraci , 2006 n=NA	Weekly Epi CDDP Paclitaxel 120 mg/m2 versus Every three weeks Epi Paclitaxel 175 mg/m2	LABC	
Fraci , 2005 n=NA	Weekly Epi CDDP Paclitaxel 120 mg/m2 versus Every three weeks Epi Paclitaxel 175 mg/m2	Metastatic	
Sikov , 2002 n=NA	Weekly Paclitaxel 150 mg/m2 versus Split D1,8 every three weeks Paclitaxel 175 mg/m2	Metastatic	

References

65279;Rivera , 2008:

Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. *Cancer* 2008;112:1455-61 [[18300256](#)] [10.1002/cncr.23321](#)

Tabernero , 2004:

Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Antn A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. *Ann Oncol* 2004;15:1358-65 [[15319242](#)] [10.1093/annonc/mdh349](#)

Sedky , 2002:

Sedky L, El-Dine IS, Hazme B, Samir Motawe S, Fahmi R. Weekly docetaxel vs every 3-week in advanced breast cancer: results of a pilot comparative study. *Proc Am Soc Clin Oncol* 2002;21. abstr 2013.

Willemse , 2007:

Willemse P, Munck L, Creemers GJ, et al. A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer *Breast Cancer Res Treat* 2007;106(Suppl. 1):S70. abstract 1083.

Gradishar , 2009:

Gradishar WJ, Krasnojon D, Cheporov S, et al. Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer *Eur J Cancer* 2007;5(Suppl. 4):215. abstr P2106.

Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. *J Clin Oncol* 2009;27:3611-9 [[19470941](#)] [10.1200/JCO.2008.18.5397](#)

Fountzilas , 2008:

Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. *Breast Cancer Res Treat* 2009;115:87-99 [[18483853](#)] [10.1007/s10549-008-0047-9](#)

Khoo , 2006:

Khoo KS, Manzoor Zaidi SH, Srimuninnimit V, Song S, Nair R, Ngelangel CA, Bustam A, Reece WH, Lehnert M Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study. *Eur J Cancer* 2006;42:1797-806 [[16846734](#)] [10.1016/j.ejca.2006.05.001](#)

CLGB 9840 (Seidman), 2008:

Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. *J Clin Oncol* 2008;26:1642-9 [[18375893](#)] [10.1200/JCO.2007.11.6699](#)

Frasci , 2006:

Frasci G, D'Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, De Rosa V, Iodice G, Rubulotta MR, Comella G Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. *Br J Cancer* 2006;95:1005-12 [[17047649](#)] [10.1038/sj.bjc.6603395](#)

Frasci , 2005:

Frasci G, DAiuto G, Comella P, et al. Weekly cisplatin-epirubicin-paclitaxel with G-CSF support (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC) *J Clin Oncol* 2005;23(16S, June 1 Suppl.):580

Sikov , 2002:

Sikov WM, Akerley W, Kahanic S, et al. Multicenter, 3-arm randomized study of high-dose weekly paclitaxel (HDWP) versus standard-dose weekly paclitaxel (SDWP) for metastatic breast cancer (MBC) *Proc Am Soc Clin Oncol* 2002;21. abstr 134

6 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.